Mammoth Biosciences
Mammoth Biosciences is pioneering CRISPR technology. With a distinguished team full of deep technical expertise, including CRISPR co-inventor and Nobel Laureate Dr. Jennifer Doudna, Mammoth is working to permanently cure genetic diseases with one-time in vivo delivery of CRISPR therapeutics. While legacy CRISPR systems exceed payload restrictions, Mammoth Biosciences is creating proprietary next-generation CRISPR systems, which are smaller, have a higher fidelity, greater multiplexing potential, and can enable genome editing results that might not be possible with other Cas systems. Mammoth Biosciences has made significant progress in commercializing its CRISPR platform, including two therapeutic partnerships with major pharma players Bayer and Vertex totaling over 1.6 billion in potential revenue for the Company.